mRNA Experts acknowledge many faults in mRNA vaccines

But they still seem to believe that the vaccines helped on balance. Most deaths were among the elderly, who probably died WITH rather than FROM Covid. Among the under-65s, most infections were minor. A few lives may have been saved by the vaccines but some were lost from vaccine effects too

A trio of experts from one of the birthplaces of mRNA breakthroughs represented by Drew Weissman, MD, PhD Perelman School of Medicine, University of Pennsylvania, and along with Katalin Kariko, winner of the Nobel Prize in Physiology or Medicine in 2023 for their role in driving mRNA-related discovery directly influencing the development of the Pfizer—BioNTech COVID-19 vaccine (BNT162b2) discuss the need to look at mRNA technology, beyond the COVID-19 vaccines.

In a way, a code word to acknowledge that these products in the form delivered to the world as a mass countermeasure/immunization scheme during a global pandemic are not ready for more refined therapeutic delivery. Put another way the products as represented by the vaccines are by no means ready for prime time! Why? One of the true authorities on the subject of mRNA, Weissman and University of Pennsylvania colleagues, point out in their recent paper published in The Lancet problems, or challenges ongoing with mRNA stability, duration of expression, targetability, and the like, but also introduces scientific advances to harden these products. These products were rushed to market in the pandemic. Key preclinical steps such as pharmacodynamics were all but bypassed due to the exigencies of the time. As a deadly virus spread, government health agencies and industry decided that acceleration of mRNA vaccine delivery for mass immunization was acceptable.

Yet because of the emergency conditions and the medical establishment’s declaration that the vaccines saved millions of lives, any externalities continue to be swept under the carpet of history. And these are externalities that derive from the gaps called out by one of the most notable authorities on the topic of mRNA technology. Advancing this medicinal technology in more refined therapeutics necessitates improvements they discuss in their paper. The good news, industry is quietly capitalizing on advancements in science to stabilize these products. The bad news, any externalities adversely affecting what is likely a relatively small percentage of the masses during the pandemic don’t exist according to the medical establishment. Is human suffering a consequence of advancement?

Declaring that the recent COVID-19-driven advancements ushered in a new era in medicine powered by mRNA-based therapeutics, “the rapid, potent, and transient nature of mRNA-encoded proteins” less any nucleus penetration or risk of genomic integration positions mRNA-based medicine as “desirable tools for treatment of a range of diseases, from infectious diseases to cancer and monogenic disorders (inheritance of a single gene mutations).

Yet this view evades over some fundamental challenges that the medical research establishment will not come out and admit publicly! At least in a minority of cases, for example, the spike protein generated by the mRNA does not just flush out of the system as declared by the boosters. Peer-reviewed study after peer-reviewed study finds evidence of the spike protein distribution sending the potentially toxic protein to various tissues or organs in the human body. This has become fact yet the medical research establishment will not accept this reality, at least not yet.

Or perhaps they have and experts such as Dr. Drew Weissman, the American physician-immunologist known for this contributions to RNA biology, whose work underlies the development of the mRNA vaccines of BioNTech (Pfizer), does perhaps acknowledge the need to advance the technology in this latest piece published in The Lancet.

While he and Penn-based colleagues declare in their recent paper, “The rapid pace and ease of mass-scale manufacturability of mRNA-based therapeutics supported the global response to the COVID-19 pandemic,” they explicitly acknowledge that “challenges remain with regards to mRNA stability, duration of expression, delivery efficiency and targetability.” Acknowledging and overcoming these fundamental challenges, an admission in many ways, are absolutely vital before any broadening of applicability for mRNA therapeutics can happen.

Put in simple terms the trio, rightly considered an authority on the topic, argue in this latest entry that it’s not prime time for mRNA technology!

But hold on, didn’t we just inject hundreds of millions of people worldwide with mRNA vaccines? Yes, of course, and that was an emergency use authorization scenario in an emergency setting. And while the jabs were ultimately approved by the Food and Drug Administration (except now for children 6 months to 11, which are still investigational), driving their logic is the assumption that the benefits given the COVID-19 pandemic outweighed any costs or externalities, which medical authorities and regulators resist any acknowledgment.

Of course, the evidence of these externalities exists in persons that combat ongoing issues, injuries derived from the mass immunization program. TrialSite has amassed more than enough evidence along with partner React19, the largest COVID-19 vaccine injury advocacy group worldwide.

TrialSite’s founder, Daniel O’Connor, shared, “This most recent piece in The Lancet represents yet another admission as to the reality that it’s not prime time yet for the mRNA therapeutic technology.” The TrialSite founder said, “You could not find a better, more authoritative source than Dr. Weissman, who, along with Katalin Kariko, received the Nobel Prize in Physiology or Medicine in 2023 for the discoveries of these two leading to the mRNA technology today as we know it.”

TrialSite has tracked a series of papers and studies now representing authoritative figures in science who come forth via academic papers discussing the gap between the existing platform in use, billions of doses administered, and the needs for better stability, efficient delivery, and targetability, as Weissman and colleagues postulate.

For example, TrialSite recently reported on the ex-Moderna scientists and the Northeastern University professor that recently had a similar paper published.

See the TrialSite piece based on the authored by four ex-Moderna scientists and a Northeastern University professor, the paper calls attention to serious limitations in the existing mRNA technology now on the market. See “Bombshell? Ex-Moderna Preclinical Scientists Acknowledge Serious Safety Concern with Current mRNA Technology..”

Weissman and colleagues acknowledge the ongoing need to learn “rapidly” from the growing number of both preclinical and clinical trials testing mRNA-based therapeutics and vaccines.

The goal: to optimize what essentially in the minds of the authors are a proven medical technology, based on what Weissman and colleagues breakdown as advances in mRNA technology, many overlapping with those discussed by the ex-Moderna scientists and in select other papers published in TrialSite.

How are these advancements being used in Immunotherapeutics, protein replacement therapy, and genomic editing? How is targetability improving in that scientists can, with more predictability, deliver mRNA to “desired specific cell types and organs?”

These breakthroughs, or better, incremental advancements are what is needed to validate the “development of the next generation of targeted mRNA therapeutics.”

Behind The Lancet paywall, we must respect their boundaries, as we have our own for economic sustainability, so for those tracking these trends the Weissman piece most certainly should be studied.

But here at TrialSite, we think it’s fair and important to ask about those gaps, the deficiencies in the mRNA technology that were clearly part of the emergency countermeasure product administered by over a billion people. Considering externalities in what, in essence, was a declared war against a pathogen, why is there such resistance to recognize and accept publicly what one of the true inventors of the technology has acknowledged?

https://www.trialsitenews.com/a/mrna-nobel-prize-winner-drew-weissman-verifies-mrna-platform-needs-significant-advancement-before-prime-time-for-therapeutics-fb89e163

*************************************************

Also see my other blogs. Main ones below:

http://edwatch.blogspot.com (EDUCATION WATCH)

http://antigreen.blogspot.com (GREENIE WATCH)

http://pcwatch.blogspot.com (POLITICAL CORRECTNESS WATCH)

http://australian-politics.blogspot.com (AUSTRALIAN POLITICS)

http://snorphty.blogspot.com (TONGUE-TIED)

https://immigwatch.blogspot.com (IMMIGRATION WATCH)

https://awesternheart.blogspot.com (THE PSYCHOLOGIST)

http://jonjayray.com/blogall.html More blogs

*********************************************************